Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Refining Renal Prognosis in Patients with Cirrhosis

Clin Gastroenterol Hepatol; 2017 Jul; Puthumana, et al

Publish date:: July 13, 2017

Measuring urinary levels of interleukin 18 (IL18) and neutrophil gelatinase-associated lipocalin (NGAL) in patients with cirrhosis can help distinguish between acute tubular necrosis and other causes of acute kidney injury. To reach that conclusion, researchers reviewed 8 studies, including over 1,000 patients with cirrhosis. Their analysis revealed:

Urinary IL18 and NGAL levels were able to identify patients who would die in the hospital or within 90 days.
The researchers suggest that both biomarkers may help estimate patients’ prognosis and guide the best treatment options for patients with cirrhosis.

Citation:

Puthumana J, Ariza X, Belcher JM, et al. Urine interleukin 18 and lipocalin 2 are biomarkers of acute tubular necrosis in patients with cirrhosis: a systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2017;15:1003-1013.e3.

This Week's Must Reads

Younger adults present with more advanced esophageal adenocarcinoma,

PDAC: Tumor reduction after neoadjuvant therapy may predict postsurgical survival,

Endoscopic intragastric balloon improved NASH parameters,

Autologous fecal microbiota transplantation helped maintain weight loss after ‘green’ Mediterranean diet,

Cryoballoon, cryospray found equivalent for eradicating Barret’s esophagus,

Must Reads in Liver Disease

Endoscopic intragastric balloon improved NASH parameters,

Lusutrombopag found safe, effective for severe thrombocytopenia in patients with hepatocellular carcinoma,

Bariatric surgery achieved long-term resolution of NASH without worsening fibrosis,

Anti-CD8a, anti-IL-17A antibodies improved immune disruption in mice with history of NASH,

Studies eyes risks for poor outcomes in primary sclerosing cholangitis,